clinical trial · NCT05083390
Norursodeoxycholic Acid vs. Placebo in NASH
Dr. Falk Pharma GmbH·phase2·unknown·n = 363
Nonalcoholic SteatohepatitisnorUrsodeoxycholic acid
brief summary
This is a double-blind, randomised, multi-centre, placebo-controlled, comparative, phase IIb trial. The trial will be conducted with three treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with either 1500 mg/d or 1000 mg/d norUDCA tablets vs. placebo tablets for the treatment of NASH.
started
Jul 8, 2019
primary completion
Jan 1, 2025
completion
Apr 1, 2025
last updated
Feb 20, 2024
official title
Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol